Synthesis 2011(16): 2619-2624  
DOI: 10.1055/s-0030-1260116
PAPER
© Georg Thieme Verlag Stuttgart ˙ New York

A Concise Synthesis of 6-Oxa-3-azabicyclo[3.1.1]heptane Hydrotosylate

Donn G. Wishkaa, Paul Beagleyb, Jessica Lyonb, Kathleen A. Farleya, Daniel P. Walker*a
a Pfizer Worldwide Research & Development, Eastern Point Rd., Groton, CT 06340, USA
Fax: +1(860)6860013; e-Mail: daniel.p.walker.pfizer@gmail.com;
b Peakdale Molecular Ltd., Peakdale Science Park, Sheffield Rd., Chapel-en-le-Frith, High Peak, SK23 0PG, UK
Further Information

Publication History

Received 4 May 2011
Publication Date:
14 July 2011 (online)

Abstract

Bridged bicyclic morpholines are important building blocks in medicinal chemistry research. The bicyclic morpholine 6-oxa-3-azabicyclo[3.1.1]heptane (2a) is of particular interest as a morpholine isostere because it is achiral and shows properties similar to that of morpholine based on a derived analogue. The first synthesis of morpholine 2a (tosylate salt) is described. The six-step sequence begins with inexpensive starting materials and uses straightforward chemistry.

    References and notes

  • 1 Brickner SJ. Barbachyn MR. Hutchinson DK. Manninen PR. J. Med. Chem.  2008,  51:  1981 
  • 2 Barker AJ. Gibson KH. Grundy W. Godfrey AA. Barlow JJ. Healy MP. Woodburn JR. Ashton SE. Curry BJ. Scarlett L. Henthorn L. Richards L. Bioorg. Med. Chem. Lett.  2001,  11:  1911 
  • 3 Kasper S. El Giamal N. Hilger E. Expert Opin. Pharmacother.  2000,  1:  771 
  • 4a Griffin RJ. Fontana G. Golding BT. Guiard S. Hardcastle IR. Leahy JJJ. Martin N. Richardson C. Rigoreau L. Stockley M. Smith GCM. J. Med. Chem.  2005,  48:  569 
  • 4b Blizzard TB. DiNinno F. Morgan JD. Chen HY. Wu JY. Gude C. Kim S. Chan W. Birzin ET. Yang YT. Pai L.-Y. Zhang Z. Hayes EC. DaSilva CA. Tang W. Rohrer SP. Schaeffer JM. Hammond ML. Bioorg. Med. Chem. Lett.  2004,  14:  3861 
  • 4c Roecker AJ. Coleman PJ. Mercer SP. Schreier SD. Buser CA. Walsh ES. Hamilton K. Lobell RB. Tao W. Diehl RE. South VJ. Davide JP. Kohl NE. Yan Y. Kuo LC. Li C. Fernandez-Metzler C. Mahan EA. Prueksaritanont T. Hartman GD. Bioorg. Med. Chem. Lett.  2007,  17:  5677 
  • 4d Venkatesan AM. Chen Z. Santos OD. Dehnhardt C. Santos ED. Ayral-Kaloustian S. Mallon R. Hollander I. Feldberg L. Lucas J. Yu K. Chaudhary I. Mansour TS. Bioorg. Med. Chem. Lett.  2010,  20:  5869 
  • 4e Zask A. Kaplan J. Verheijen JC. Richard DJ. Curran K. Brooijmans N. Bennett EM. Toral-Barza L. Hollander I. Ayral-Kaloustian S. Yu K. J. Med. Chem.  2009,  52:  7942 
  • 4f Tsuo H.-R. MacEwan G. Birnberg G. Zhang N. Brooijmans N. Toral-Barza L. Hollander I. Ayral-Kaloustian S. Yu K. Bioorg. Med. Chem. Lett.  2010,  20:  2259 
  • 5 Wuitschik G. Carreira EM. Wagner B. Fischer H. Parrilla I. Schuler F. Rogers-Evans M. Müller K. J. Med. Chem.  2010,  53:  3227 
  • 6a Newth FH. Wiggins LF. J. Chem. Soc.  1948,  155 
  • 6b Connolly TJ. Considine JL. Ding Z. Forsatz B. Jennings MN. MacEwan MF. McCoy KM. Place DW. Sharma A. Sutherland K. Org. Process Res. Dev.  2010,  14:  459 
  • 7a v. Braun J. Leistner W. Chem. Ber.  1926,  59:  2323 
  • 7b Axten JM, Brady GP, Gallagher TF, Heerding DA, Medina JR, and Romeril SP. inventors; WO  2010,120,854.  2010; Chem. Abstr. 2010, 153, 555216
  • 8 Portoghese PS. Turcotte JG. J. Med. Chem.  1971,  14:  288 
  • 9 Flohr A, Jakob-Roetne R, Norcross RD, and Riemer C. inventors; WO  2003,049,741.  2003; Chem. Abstr. 2003, 139, 53026
  • 10 Wuitschik G. Rogers-Evans M. Buckl A. Bernasconi M. Märki M. Godel T. Fischer H. Wagner B. Parrilla I. Schuler F. Schneider J. Alker A. Schweizer WB. Müller K. Carreira EM. Angew. Chem. Int. Ed.  2008,  47:  4512 
  • 11a Paul R. Williams RP. Cohen E. J. Org. Chem.  1975,  40:  1653 
  • 11b Pearlman BA. inventors; WO  1999,024,393.  1999; Chem. Abstr. 1999, 130, 338099
  • 11c Perrault WR. Pearlman BA. Godrej DB. Jeganathan A. Yamagata K. Chen JJ. Lu CV. Herrington PM. Gadwood RC. Chan L. Lyster MA. Maloney MT. Moeslein JA. Greene ML. Barbachyn MR. Org. Process Res. Dev.  2003,  7:  533 
  • 12a Higgins RH. Eaton QL. Worth L. Peterson MV. J. Heterocycl. Chem.  1987,  24:  255 
  • 12b Higgins RH. Watson MR. Faircloth WJ. Eaton QL. Jenkins H. J. Heterocycl. Chem.  1988,  25:  383 
  • 13 Cf: Morie T. Kato S. Harada H. Matsumoto J. Heterocycles  1994,  38:  1033 
  • 14 The importance of forming a potassium enolate to effect efficient intramolecular cyclization on a similar carbocyclic system has been previously observed, see: Nicolaou KC. Magolda RL. Claremon DA. J. Am. Chem. Soc.  1980,  102:  1404 
  • 15 Geiger C. Zelenka C. Lehmkuhl K. Schepmann D. Englberger W. Wünsch B. J. Med. Chem.  2010,  53:  4212 
  • 16 Ohkubo M. Kuno A. Katsuta K. Ueda Y. Shirakawa K. Chem. Pharm. Bull.  1996,  44:  778 
  • 17 Cf: Sasaki T. Eguchi S. Suzuki T. J. Org. Chem.  1980,  45:  3824 
  • 18 Di L. Kerns EH. Hong Y. Chen H. Int. J. Pharm.  2005,  297:  110 
19

Conditions used in the workup of the borane reduction of compound 12, see experimental section for further details.